Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer

Background To the authors' knowledge, there are no approved therapies for recurrent, metastatic (R/M) salivary gland carcinoma (SGC), but molecularly targeted therapies warrant ongoing investigation. In the current study, the authors have reported on the efficacy of tipifarnib in patients with aggressive HRAS ‐mutant, R/M SGC. Methods The current prospective, nonrandomized, multicenter, international cohort study involved 8 centers and was...